Presence of EBV antigens detected by a sensitive method in pediatric and adult Diffuse Large B‐cell lymphomas

MANGIATERRA, TAMARA S.; DE DIOS SOLER, MARCELA; OVIEDO, NOELIA; COLLI, SANDRA; PRECIADO, MARIA V.; SORIA, MARCELA; GALLUZO, LAURA; DE MATTEO, ELENA; CHABAY, PAOLA

INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER.

JOHN WILEY & SONS INC

Lugar: New York; Año: 2023

0020-7136

In 2017, the World Health Organization (WHO) confirmed a new entity, Epstein Barr virus (EBV)+ Diffuse large B cell lymphoma (DLBCL), not otherwise specified (NOS). Traces of EBV transcripts were described in lymphomas, including DLBCL, that were diagnosed as EBV negative by conventional methods. The aim of this study was to detect viral genome by qPCR, as well as LMP1 and EBNA2 transcripts, with a more sensitive method in DLBCL cases from Argentina. Fourteen cases originally considered as EBV negative expressed LMP1 and/or EBNA2 transcripts. In addition, LMP1 and/or EBNA2 transcripts were also observed in bystander cells. However, EBERs+ cells cases by conventional ISH showed higher numbers of cells with LMP1 transcripts and LMP1 protein. In the cases that were EBERS- tumor cells but with expression of LMP1 and/or EBNA2 transcripts, the viral load was below the limit of detection. This study provides further evidence that EBV could be detected in tumor cells by more sensitive methods. However, higher expression of the most important oncogenic protein, LMP1, as well as increased viral load, are only observed in cases with EBERs+ cells by conventional ISH, suggesting that traces of EBV might not display a key role in DLBCL pathogenesis.